Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mochida Pharmaceutical Co., Ltd. ( (JP:4534) ) has issued an announcement.
Mochida Pharmaceutical has agreed to take over the manufacturing and marketing approval for URECE Tablets, a dotinurad-based treatment for gout and hyperuricemia, from FUJI YAKUHIN in Japan and to acquire associated assets including patents and trademarks for 13.5 billion yen. The move shifts Mochida from distributor and joint promoter to full marketing authorization holder, aiming to secure stable supply, strengthen its cardiovascular and hyperuricemia portfolio, and internalize roughly 4.6 billion yen in annual product sales as intangible assets with no assumed liabilities.
The acquisition builds on a collaboration dating back to 2017, under which FUJI YAKUHIN developed and launched URECE in 2020 while Mochida handled distribution and joint information activities. By consolidating rights and approvals, Mochida is positioned to deepen its presence in treatments for lifestyle-related diseases, enhance control over commercialization and medical information provision, and potentially improve profitability and strategic flexibility in its core therapeutic area.
The most recent analyst rating on (JP:4534) stock is a Hold with a Yen3985.00 price target. To see the full list of analyst forecasts on Mochida Pharmaceutical Co., Ltd. stock, see the JP:4534 Stock Forecast page.
More about Mochida Pharmaceutical Co., Ltd.
Mochida Pharmaceutical Co., Ltd. is a Japanese drugmaker established in 1913 that focuses on research and development of innovative prescription medicines. Its core businesses center on cardiovascular medicine, gastroenterology, obstetrics and gynecology, psychiatry, as well as treatments for intractable diseases and generics including biosimilars, with multiple products for lifestyle-related conditions such as hyperlipidemia, hypertension and hyperuricemia in the domestic market.
YTD Price Performance: 4.38%
Average Trading Volume: 37,141
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen125.6B
See more data about 4534 stock on TipRanks’ Stock Analysis page.